Journal article
Oncolytic viruses: how “lytic” must they be for therapeutic efficacy?
Abstract
Oncolytic viruses (OVs) preferentially target and kill cancer cells without affecting healthy cells through a multi-modal mechanism of action. While historically the direct killing activity of OVs was considered the primary mode of action, initiation or augmentation of a host antitumor immune response is now considered an essential aspect of oncolytic virotherapy. To improve oncolytic virotherapy, many studies focus on increasing virus …
Authors
Davola ME; Mossman KL
Journal
OncoImmunology, Vol. 8, No. 6,
Publisher
Taylor & Francis
Publication Date
June 3, 2019
DOI
10.1080/2162402x.2019.1596006
ISSN
2162-4011